Iovance Biotherapeutics (IOVA) announced that on August 21, 2025, the Company approved the grant of inducement stock options covering an aggregate of 182,370 shares of Iovance’s common stock to 20 new, non-executive employees.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics Amends Sale Agreement with Jefferies
- Iovance Biotherapeutics Gains Health Canada Approval
- Home Depot reports Q2 results, SoftBank invests $2B in Intel: Morning Buzz
- Iovance Biotherapeutics’ Canadian Approval of AMTAGVI: A Milestone in T Cell Therapy and Stock Growth Potential
- Iovance Amtagvi receives Health Canada approval for advanced melanoma